Login / Signup

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis.

Vivien HäußlerFriederike UferJana PöttgenChristine WolschkeManuel A FrieseNicolaus KrögerChristoph HeesenJan-Patrick Stellmann
Published in: Annals of clinical and translational neurology (2021)
aHSCT suppresses inflammatory activity more effectively than alemtuzumab and might enable improvement of overall disability and cognition in MS.
Keyphrases
  • multiple sclerosis
  • white matter
  • mild cognitive impairment
  • signaling pathway
  • oxidative stress
  • mass spectrometry
  • ms ms